Mohanad Mossalam, Ph.D.
Affiliations: | 2012 | Pharmaceutics and Pharmaceutical Chemistry | University of Utah, Salt Lake City, UT |
Area:
Molecular Biology, Polymer Chemistry, OncologyGoogle:
"Mohanad Mossalam"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Carol S. Lim | grad student | 2012 | University of Utah | |
| (Subcellular targeting: Delivering therapeutics to the next level.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Matissek KJ, Okal A, Mossalam M, et al. (2014) Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax. Pharmaceutical Research. 31: 2503-15 |
| Matissek KJ, Mossalam M, Okal A, et al. (2013) The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria. Molecular Pharmaceutics. 10: 3592-602 |
| Okal A, Mossalam M, Matissek KJ, et al. (2013) A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells. Molecular Pharmaceutics. 10: 3922-33 |
| Reaz S, Mossalam M, Okal A, et al. (2013) A single mutant, A276S of p53, turns the switch to apoptosis. Molecular Pharmaceutics. 10: 1350-9 |
| Davis JR, Mossalam M, Lim CS. (2013) Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2. Molecular Pharmaceutics. 10: 1340-9 |
| Mossalam M, Soto J, Lim CS, et al. (2013) Solid phase synthesis of mitochondrial triphenylphosphonium-vitamin E metabolite using a lysine linker for reversal of oxidative stress. Plos One. 8: e53272 |
| Matissek KJ, Mossalam M, Okal A, et al. (2013) Abstract 791: Targeting small domains of p53 to mitochondrial Bcl-XL for cancer therapy. Cancer Research. 73: 791-791 |
| Okal A, Mossalam M, Matissek KJ, et al. (2013) Abstract 790: An alternative tetramerization domain of p53 for exclusive homo-oligomerization and potent tumor suppression. Cancer Research. 73: 790-790 |
| Constance JE, Woessner DW, Matissek KJ, et al. (2012) Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. Molecular Pharmaceutics. 9: 3318-29 |
| Davis JR, Mossalam M, Lim CS. (2012) Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction. Pharmaceutical Research. 29: 3455-63 |